Ann: Quarterly Activity Report & Appendix 4C - 31 December 2020, page-18

Interesting quarterly, a little underwhelming from a revenue point of view however plenty of reasons to buy and hold.

Capacity is now at 1.3M a month for Pascal plus 300K for Galileo.

Considering they only sold c.800K units for the whole quarter, and by looking at the expenditure it looks like Atomo are building a stockpile for a larger order.

If Atomo were selling through their entire inventory, revenue would be close to $17M a quarter (at $3.50 per device).

Elion platform launch imminent which will open additional diseases and revenue streams. Access Bio deal alone will soak up 600K units a quarter to reach their take or pay deal commitment.

No mention of DIVOC or Indian approval, so that deal must have fallen by the wayside.